Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study.

Wright CE, Fraser SD, Brindle K, Morice AH, Hart SP, Crooks MG.

ERJ Open Res. 2017 Dec 14;3(4). pii: 00100-2017. doi: 10.1183/23120541.00100-2017. eCollection 2017 Oct.

2.

The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis.

Fraser SDS, Fenton A, Harris S, Shardlow A, Liabeuf S, Massy ZA, Burmeister A, Hutchison CA, Landray M, Emberson J, Kalra PA, Ritchie JP, Cockwell P, Taal MW.

Mayo Clin Proc. 2017 Nov;92(11):1671-1681. doi: 10.1016/j.mayocp.2017.08.021. Epub 2017 Nov 1. Review. Erratum in: Mayo Clin Proc. 2017 Dec;92 (12 ):1866.

PMID:
29101935
3.

The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study.

Shardlow A, McIntyre NJ, Fraser SDS, Roderick P, Raftery J, Fluck RJ, McIntyre CW, Taal MW.

PLoS Med. 2017 Oct 10;14(10):e1002400. doi: 10.1371/journal.pmed.1002400. eCollection 2017 Oct.

4.

Epidemiology of AKI: Utilizing Large Databases to Determine the Burden of AKI.

Sawhney S, Fraser SD.

Adv Chronic Kidney Dis. 2017 Jul;24(4):194-204. doi: 10.1053/j.ackd.2017.05.001. Review.

5.

A Systematic Review of the Prevalence and Associations of Limited Health Literacy in CKD.

Taylor DM, Fraser SDS, Bradley JA, Bradley C, Draper H, Metcalfe W, Oniscu GC, Tomson CRV, Ravanan R, Roderick PJ; ATTOM investigators.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1070-1084. doi: 10.2215/CJN.12921216. Epub 2017 May 9. Review.

6.

Validity of estimated prevalence of decreased kidney function and renal replacement therapy from primary care electronic health records compared with national survey and registry data in the United Kingdom.

Iwagami M, Tomlinson LA, Mansfield KE, Casula A, Caskey FJ, Aitken G, Fraser SDS, Roderick PJ, Nitsch D.

Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii142-ii150. doi: 10.1093/ndt/gfw318.

7.

The ascending rank of chronic kidney disease in the global burden of disease study.

Jager KJ, Fraser SDS.

Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii121-ii128. doi: 10.1093/ndt/gfw330. Review.

PMID:
28201666
8.

Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis.

Fraser SD, Sadofsky LR, Kaye PM, Hart SP.

Sci Rep. 2016 Dec 8;6:38689. doi: 10.1038/srep38689.

9.

Chronic kidney disease: identification and management in primary care.

Fraser SD, Blakeman T.

Pragmat Obs Res. 2016 Aug 17;7:21-32. eCollection 2016. Review.

10.

Multimorbidity in people with chronic kidney disease: implications for outcomes and treatment.

Fraser SD, Taal MW.

Curr Opin Nephrol Hypertens. 2016 Nov;25(6):465-472. Review.

PMID:
27490909
11.

KDIGO-based acute kidney injury criteria operate differently in hospitals and the community-findings from a large population cohort.

Sawhney S, Fluck N, Fraser SD, Marks A, Prescott GJ, Roderick PJ, Black C.

Nephrol Dial Transplant. 2016 Jun;31(6):922-9. doi: 10.1093/ndt/gfw052. Epub 2016 Apr 7.

12.

Where now for proteinuria testing in chronic kidney disease?: Good evidence can clarify a potentially confusing message.

Fraser SD, Roderick PJ, Taal MW.

Br J Gen Pract. 2016 Apr;66(645):215-7. doi: 10.3399/bjgp16X684721. No abstract available.

13.

The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study.

Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, Shardlow A, Taal MW.

BMC Nephrol. 2015 Dec 1;16:193. doi: 10.1186/s12882-015-0189-z.

14.

Perspectives on differing health outcomes by city: accounting for Glasgow's excess mortality.

Fraser SD, George S.

Risk Manag Healthc Policy. 2015 Jun 17;8:99-110. doi: 10.2147/RMHP.S68925. eCollection 2015. Review.

15.

Timeliness in chronic kidney disease and albuminuria identification: a retrospective cohort study.

Fraser SD, Parkes J, Culliford D, Santer M, Roderick PJ.

BMC Fam Pract. 2015 Feb 13;16:18. doi: 10.1186/s12875-015-0235-8.

16.

Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey for England.

Fraser SD, Aitken G, Taal MW, Mindell JS, Moon G, Day J, O'Donoghue D, Roderick PJ.

PLoS One. 2015 Feb 20;10(2):e0118676. doi: 10.1371/journal.pone.0118676. eCollection 2015.

17.

Skin autofluorescence and all-cause mortality in stage 3 CKD.

Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, Taal MW.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1361-8. doi: 10.2215/CJN.09510913. Epub 2014 May 29.

18.

Assessment of proteinuria in patients with chronic kidney disease stage 3: albuminuria and non-albumin proteinuria.

Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre C, Fluck R, Taal MW.

PLoS One. 2014 May 27;9(5):e98261. doi: 10.1371/journal.pone.0098261. eCollection 2014.

19.

Chronic kidney disease, albuminuria and socioeconomic status in the Health Surveys for England 2009 and 2010.

Fraser SD, Roderick PJ, Aitken G, Roth M, Mindell JS, Moon G, O'Donoghue D.

J Public Health (Oxf). 2014 Dec;36(4):577-86. doi: 10.1093/pubmed/fdt117. Epub 2013 Nov 25.

PMID:
24277777
20.

Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care.

Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, Taal MW.

BMC Fam Pract. 2013 Jun 24;14:88. doi: 10.1186/1471-2296-14-88.

21.

Socio-economic disparities in the distribution of cardiovascular risk in chronic kidney disease stage 3.

Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, Taal MW.

Nephron Clin Pract. 2012;122(1-2):58-65. doi: 10.1159/000348835. Epub 2013 Mar 21.

PMID:
23548499
22.

Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review.

Fraser SD, Roderick PJ, Casey M, Taal MW, Yuen HM, Nutbeam D.

Nephrol Dial Transplant. 2013 Jan;28(1):129-37. doi: 10.1093/ndt/gfs371. Epub 2012 Dec 4. Review.

PMID:
23222414
23.

Small- and wide-angle X-ray scattering (SWAXS) for quantification of aspirin content in a binary powder mixture.

Hodzic A, Llusa M, Fraser SD, Scheibelhofer O, Koller DM, Reiter F, Laggner P, Khinast JG.

Int J Pharm. 2012 May 30;428(1-2):91-5. doi: 10.1016/j.ijpharm.2012.02.048. Epub 2012 Mar 8.

PMID:
22425676
24.

Cycling for transport and public health: a systematic review of the effect of the environment on cycling.

Fraser SD, Lock K.

Eur J Public Health. 2011 Dec;21(6):738-43. doi: 10.1093/eurpub/ckq145. Epub 2010 Oct 6. Review.

PMID:
20929903
25.

A betaPix Pak2a signaling pathway regulates cerebral vascular stability in zebrafish.

Liu J, Fraser SD, Faloon PW, Rollins EL, Vom Berg J, Starovic-Subota O, Laliberte AL, Chen JN, Serluca FC, Childs SJ.

Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):13990-5. Epub 2007 Jun 15.

26.

Semaphorin-plexin signaling guides patterning of the developing vasculature.

Torres-Vázquez J, Gitler AD, Fraser SD, Berk JD, Van N Pham, Fishman MC, Childs S, Epstein JA, Weinstein BM.

Dev Cell. 2004 Jul;7(1):117-23.

27.

The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4.

Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA.

EMBO J. 2001 Jul 16;20(14):3821-30.

28.
29.

5'-3' interactions in regulation of translation in Xenopus early embryos.

Browder LW, Wilkes-Johnston J, Fraser SD.

Biochem Cell Biol. 1997;75(6):739-48.

PMID:
9599663
30.

Effects of c-myc first exons and 5' synthetic hairpins on RNA translation in oocytes and early embryos of Xenopus laevis.

Fraser SD, Wilkes-Johnston J, Browder LW.

Oncogene. 1996 Mar 21;12(6):1223-30.

PMID:
8649824
31.

It is time to think.

Fraser SD.

J Prosthet Dent. 1966 Nov-Dec;16(6):1162-4. No abstract available.

PMID:
5223839

Supplemental Content

Loading ...
Support Center